News

An independent Safety Monitoring Board (SMB) has completed the third scheduled safety analysis for Vical’s phase 3 AIMM trial of Allovectin-7 in patients with metastatic melanoma and recommended

Emerald BioStructures (formerly deCODE biostructures) has reported a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD)

Forest Laboratories (Forest) has entered into an agreement to acquire additional rights to NXL 104. This amends the terms of its prior agreement with Novexel covering the combination

The FDA has issued a complete response letter regarding Pfizer’s New Drug Application (NDA) for Lyrica (pregabalin) capsules CV, as a monotherapy treatment for generalised anxiety disorder (GAD).

Merck & Co has decided to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis, being developed under its research collaboration with Arena Pharmaceuticals (Arena).

Solvay Seiyaku K K, the Japanese entity of Solvay Pharmaceuticals, has submitted a New Drug Application (NDA) for SA-001, a pancreatic enzyme replacement therapy agent for pancreatic exocrine

Teva-KOWA Pharma has signed a definitive agreement to acquire a majority of the outstanding shares of Taisho Pharmaceutical Industries (Taisho). As per the agreement, Teva-KOWA Pharma is expected

Questcor Pharmaceuticals has said that the FDA now considers that the company has provided a complete response to all prior action letters for its supplemental New Drug Application

SemBioSys Genetics (SemBioSys) has provided an update on its progress on plant-produced Apo AI (Milano), in light of the license agreement between Pfizer and The Medicines Company, New